DC
BLPH

Davenport & Co’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Davenport & Co’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-98,975
Closed -$514K – 977
2021
Q1 		$514K Buy
98,975
+9,750
+11% +$67.9K ﹤0.01% 527
2020
Q4 		$595K Sell
89,225
-5,250
-6% -$43K 0.01% 477
2020
Q3 		$962K Sell
94,475
-12,675
-12% -$149K 0.01% 347
2020
Q2 		$1.34M Buy
+107,150
New +$1.5M 0.02% 285

Other funds holding BLPH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Davenport & Co's BLPH Position: Q2 2021 in Review

Davenport & Co sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2021, closing a stake of 98,975 shares — an estimated $514K sold.

Davenport & Co first reported a position in BLPH in Q2 2020 and held it in 4 quarters. The position peaked at $1.34M in Q2 2020. 27 funds tracked by Wall St. Rank hold BLPH as of Q2 2021.

  • Davenport & Co reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Davenport & Co sold 98,975 Bellerophon Therapeutics, Inc. shares in Q2 2021, an estimated $514K.
  • Davenport & Co first reported a position in Bellerophon Therapeutics, Inc. in Q2 2020 and held it in 4 quarters.
  • Davenport & Co's Bellerophon Therapeutics, Inc. position peaked at $1.34M in Q2 2020.
  • 27 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2021.

Based on Davenport & Co's 13F filing for Q2 2021, filed 21 Jul 2021.